We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director
Infex Therapeutics is pleased to announce the appointment of Professor Colm Leonard as a Non-Executive Director of Infex with immediate effect. Colm will also be chairing Infex's clinical development…
Antimicrobial discovery and drug development – RSC Podcast
How do we develop drugs like antibiotics? How long does it take for such a drug to go from its inception in a research lab to use in a hospital, for example? And what people and processes are…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
This designation gives MET-X an accelerated U.S. regulatory pathway and an additional five-years of market exclusivity upon approval.
Latest News
Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director
Infex Therapeutics is pleased to announce the appointment of Professor Colm Leonard as a…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
This designation gives MET-X an accelerated U.S. regulatory pathway and an additional…
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a…
CARB-X Receives Additional $370m from U.S. Government and Wellcome
Enables continued investment in innovative projects to tackle the growing global threat…
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022
Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism
Infex Therapeutics, one of the UK’s leading infectious disease biotech companies, has…
Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
One of the UK’s leading infectious disease biotech companies has announced a breakthrough…
Infex agrees partnership with Colibri Scientific to provide services for RESP-X program
Infex Therapeutics has today announced a deal with Colibri Scientific, to provide…